AVEO Pharmaceuticals, Inc.
ANTI-NOTCH3 ANTIBODY
Last updated:
Abstract:
Monoclonal antibodies that bind and inhibit activation of human Notch3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation and/or overexpression of Notch3.
Status:
Application
Type:
Utility
Filling date:
7 Oct 2021
Issue date:
28 Jul 2022